Prevalence of Liver Cirrhosis on patients with Chronic Hepatitis B during treatment by Tenofovir Disoproxil 300 mg only at The NGaoundere Protestant Hospital in Adamawa Region Cameroon

Introduction: Hepatitis virus B infection are the major public Health concern with the implementation of hepatitis immunization program in 1984 and the chronic viral hepatitis therapy program in 2003, its prevalence rate has dropped from 8% to 2% -7% in the past few years. However, the Global Hepatitis Report (2017) estimated that nearly 257 million people worldwide were still living with chronic HBV infection, which would increase the risk of liver fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC) in those infected.

Methods: It is descriptive cross –sectional study prevalence of liver cirrhosis done on 20 patients tested positives with HBV confirmed by the following exams such as ELISA HBV, Viral Load HBV, Hepatitis D Serology Test and Five HBV Biomarkers among 75 patients presented some clinical manifestations of Chronic Hepatitis  at the NGaoundere Protestant Hospital in Adamawa Region Cameroon from June 2023 to August 2023 after receiving Ethical Clearance and Research Authorization from The Health Work of the Evangelical Lutheran Church of Cameroon (HWELCC) Chairman. Convenience sampling was done. The analysis included management of risk factors, clinical manifestations, diagnostic methods, treatment and complications of Chronic Hepatitis B.

Results: The prevalence of chronic hepatitis B on 75 patients was 26,66% and Out to 20 patients tested positive of chronic hepatitis, the prevalence of Liver Cirrhosis were 85%.

Conclusions: This study showed that the prevalence of Liver Cirrhosis estimated high to the patients tested positive with chronic hepatitis B despite tenofovir disoproxil 300 mg received caused by the non-management of Hepatitis B genotype and complications